

President) 701 East Byrd Street, Richmond, Virginia 23261-4528:

1. *Benjamin M. Susman, and Dixie L. Susman*, both of Beckley, West Virginia, as members of the Susman family control group; to acquire voting shares of Mount Hope Bankshares, Inc., and thereby indirectly acquire voting shares of Bank of Mount Hope, Inc., both in Mount Hope, West Virginia.

B. Federal Reserve Bank of St. Louis (Yvonne Sparks, Community Development Officer) P.O. Box 442, St. Louis, Missouri 63166-2034:

1. *Jeffrey Harris Lowrey MD, Millennium Trust Company LLC, custodian for Jeffrey Lowrey MD SEP IRA, both of Eads, Tennessee; Jennifer Lauren Watson, Louisville, Kentucky; John Allen Lowrey; James Richard Lowrey, and Nancy Kemp Lowrey*, all of Fairborn, Ohio; as members of the Lowrey family control group, to acquire voting shares of Germantown Capital Corporation, Inc., and thereby indirectly acquire voting shares of First Capital Bank, both in Germantown, Tennessee.

C. Federal Reserve Bank of Minneapolis (Jacquelyn K. Brunmeier, Assistant Vice President) 90 Hennepin Avenue, Minneapolis, Minnesota 55480-0291:

1. *James C. Hays, Miami Beach, Florida, individually and as a member of a group acting in concert consisting of: Barlow Banking Corporation, Iowa Falls, Iowa; John R. Barlow, Mound, Minnesota; the John R. Barlow IRA, Mound, Minnesota; William L. Mershon, Miami Beach, Florida; Stephen T. Lerum, Hamel, Minnesota; and Howard B. Wenger, Iowa Falls, Iowa*; to acquire voting shares of Northfield Bancshares, Inc., and thereby indirectly acquire voting shares of Community Resource Bank, both in Northfield, Minnesota.

Board of Governors of the Federal Reserve System, September 12, 2014.

**Michael J. Lewandowski**,  
Associate Secretary of the Board.

[FR Doc. 2014-22209 Filed 9-17-14; 8:45 am]

**BILLING CODE 6210-01-P**

## GOVERNMENT ACCOUNTABILITY OFFICE

[GAO-14-704G]

### 2014 Revision—Standards for Internal Control in the Federal Government

**AGENCY:** U.S. Government Accountability Office.

**ACTION:** Notice of document availability.

**SUMMARY:** The US Government Accountability Office (GAO) has issued its 2014 revision to the Standards for

Internal Control in the Federal Government, known as the “Green Book,” under the authority provided in 31 U.S.C. 3512 (c), (d), commonly known as the Federal Managers’ Financial Integrity Act (FMFIA). To help ensure that the standards continue to meet the needs of government managers and the audit community it serves, the Comptroller General of the United States established the Green Book Advisory Council to provide input on revisions to the “Green Book.” This 2014 revision of the standards includes the Advisory Council’s input regarding the changes. It also includes input from public comments received on the proposed revisions in the 2013 exposure draft. The changes contained in the 2014 revision to the Standards for Internal Control in the Federal Government reflect major developments in the accountability and financial management profession and emphasize specific considerations applicable to the government environment.

The 2014 revision to Standards for Internal Control in the Federal Government is available in electronic format for download from GAO’s Web page at [www.gao.gov](http://www.gao.gov) using GAO-14-704G as a report number. It will also be available for sale in hardcopy from the Government Printing Office in the near future at <http://bookstore.gpo.gov> or other GPO locations listed there. GAO-14-704G may be used to find its GPO stock number and ISBN.

**DATES:** The 2014 revision will be effective beginning with fiscal year 2016 and the FMFIA reports covering that year. Management, at their discretion, may elect to adopt the 2014 Green Book early.

**FOR FURTHER INFORMATION CONTACT:** For information on the Standards for Internal Control in the Federal Government, please submit questions electronically to [GreenBook@gao.gov](mailto:GreenBook@gao.gov) or telephonically to 202-512-9535.

**Authority:** 31 U.S.C. 3512(c), (d).

**Steven J. Sebastian**,  
Managing Director, Financial Management and Assurance, U.S. Government Accountability Office.

[FR Doc. 2014-22188 Filed 9-17-14; 8:45 am]

**BILLING CODE 1610-02-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Findings of Research Misconduct

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

*Takao Takahashi, M.D., Ph.D., University of Texas Southwestern Medical Center:* Based on the report of an investigation conducted by the University of Texas Southwestern Medical Center (UT Southwestern) and analysis conducted by ORI in its oversight review, ORI found that Dr. Takao Takahashi, currently a faculty member in the Department of Surgical Oncology, Gifu University, Graduate School of Medicine, Gifu, Japan, and formerly a Visiting Scientist in the Hamon Center for Therapeutic Oncology Research, UT Southwestern, engaged in research misconduct in research supported by National Cancer Institute (NCI), National Institutes of Health (NIH), grant U01 CA084971.

ORI found that Respondent knowingly, intentionally, and recklessly falsified data reported in four (4) publications:

- Takahashi, T., Shivapurkar, N., Reddy, J., Shigematsu, H., Miyajima, K., Suzuki, M., Toyooka, S., Zöchbauer-Müeller, S., Drach, J., Parikh, G., Zheng, Y., Feng, Z., Kroft, S.H., Timmons, C., McKenna, R.W., & Gazdar, A.F. “DNA methylation profiles of lymphoid and hematopoietic malignancies.” *Clin Cancer Res.* 10(9):2928–35, 2004 May 1 (hereafter referred to as “*CCR 2004*”); Retraction in: *Clin Cancer Res.* 19(1):307, 2013 Jan 1
- Takahashi, T., Suzuki, M., Shigematsu, H., Shivapurkar, N., Echebiri, C., Nomura, M., Stastny, V., Augustus, M., Wu, C.W., Wistuba, I.I., Meltzer, S.J., & Gazdar, A.F. “Aberrant methylation of Reprimo n human malignancies.” *Int J Cancer* 115(4):503–10, 2005 Jul 1 (hereafter referred to as “*IJC 2005*”); Retraction in: *Int J. Cancer* 132(2):498, 2013, Jan 15
- Takahashi, T., Shivapurkar, N., Reddy, J., Zheng, Y., Feng, Z., Suzuki, M., Noomura, M., Augustus, M., Yin, J., Meltzer, S.J., & Gazdar, A.F. “Aberrant promoter methylation of multiple genes during multistep pathogenesis of colorectal cancers.” *Int J Cancer* 118(4):924–31, 2006 Feb 15 (hereafter referred to as “*IJC 2006*”); Retraction in: *Int J Cancer* 132(2):499, 2013 Jan 15
- Tokuyama, Y., Takahashi, T., Okumura, N., Nonaka, K., Kawaguchi, Y., Yamaguchi, K., Osada, S., Gazdar, A., & Yoshida, K., “Aberrant methylation of heparan sulfate

glucosamine 3-O-sulfotransferase 2 genes as a biomarker in colorectal cancer." *Anticancer Res.* 30(12):4811–8, 2010 Dec (hereafter referred to as "AR 2010"); Retraction in: *Anticancer Res.* 32(11):5138, 2012 Nov.

Respondent falsified data representing glyceraldehyde 3-phosphate dehydrogenase (GAPDH) loading controls and methylated/unmethylated polymerase chain reaction (PCR) in reverse transcription-PCR (RT-PCR) gel panels.

Specifically, ORI found by a preponderance of the evidence that Respondent engaged in research misconduct by knowingly, intentionally, and recklessly falsely reporting the results of RT-PCR experiments by:

1. Reusing and relabeling an image and claiming it represents different experiments of human tumor cell lines subjected to different treatments; specifically, an identical image was used to represent the:

(a) GAPDH RT-PCR panels of several lymphoma, leukemia, multiple myeloma, and colorectal cancer cell lines in *CCR* 2004, Figures 1A and 1B, *IJC* 2005, Figure 1A, *IJC* 2006, Figures 1A and 2A, and AR 2010, Figure 1A

(b) GAPDH RT-PCR panels of the lymphoma cell lines BC-1 and Raji in *CCR* 2004, Figure 1B, lanes 1–3, and the colorectal cancer cell lines HCT116 and COLO201 in AR 2010, Figure 1C, lanes 4–6

(c) unmethylated form of p16 (p16UM) controls in the methylation-specific PCR (MSP) panels for the leukemia (Le) and multiple myeloma (MM) samples in *CCR* 2004, Figure 2

(d) p16UM MSP panels for the lymphoma (Ly) and Le samples in *CCR* 2004, Figure 2, and the unmethylated (UM) bands MSP panel for the colorectal cancer (CRC) cell line in *IJC* 2005, Figure 5.

2. Manipulating an image and claiming it represents a gel with contiguous lanes; specifically, the RT-PCR products in the lanes of gels were cropped, spliced, and pasted together to form a single image for the MSP panels in *IJC* 2006, Figure 3.

Dr. Takahashi has entered into a Voluntary Settlement Agreement (Agreement) and has voluntarily agreed for a period of three (3) years, beginning on August 26, 2014:

(1) To have his research supervised; Respondent agrees that prior to the submission of an application for U.S. Public Health Service (PHS) support for a research project on which the Respondent's participation is proposed and prior to Respondent's participation

in any capacity on PHS-supported research, Respondent shall ensure that a plan for supervision of Respondent's duties is submitted to ORI for approval; the supervision plan must be designed to ensure the scientific integrity of Respondent's research; Respondent agrees that he shall not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI; Respondent agrees to maintain responsibility for compliance with the agreed upon supervision plan;

(2) that any institution employing him shall submit, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; and

(3) to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

**FOR FURTHER INFORMATION CONTACT:**

Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8200.

**Donald Wright,**

*Acting Director, Office of Research Integrity.*

[FR Doc. 2014–22191 Filed 9–17–14; 8:45 am]

**BILLING CODE 4150–31–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Office of the Secretary**

**Findings of Research Misconduct**

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

*Makoto Suzuki, M.D., University of Texas Southwestern Medical Center:* Based on the report of an investigation conducted by the University of Texas Southwestern Medical Center (UT Southwestern) and analysis conducted by ORI in its oversight review, ORI found that Dr. Makoto Suzuki, currently a Professor in the Department of Thoracic Surgery, Kumamoto University Hospital, Kumamoto, Japan, and formerly a Visiting Scientist in the

Hamon Center for Therapeutic Oncology Research, UT Southwestern, engaged in research misconduct in research supported by National Cancer Institute (NCI), National Institutes of Health (NIH), grants P50 CA070907 and U01 CA084971.

ORI found that Respondent knowingly, intentionally, and recklessly falsified data reported in six (6) publications:

- Suzuki, M., Hao, C., Takahashi, T., Shigematsu, H., Shivapurkar, N., Sathyanarayana, U.G., Iizasa, T., Fujisawa, T., Hiroshima, K., & Gazdar, A.F. "Aberrant methylation of SPARC in human lung cancers." *Br J Cancer* 92(5):942–8, 2005 Mar 14 (hereafter referred to as "BJC 2005–1"); Retraction in: *Br J Cancer* 108(3):744, 2013 Feb 19
- Suzuki, M., Shigematsu, H., Shames, D.S., Sunaga, N., Takahashi, T., Shivapurkar, N., Iizasa, T., Frankel, E.P., Minna, J.D., Fujisawa, T., & Gazdar, A.F. "DNA methylation associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers." *Br J Cancer* 93(9):1029–37, 2005 Oct 31 (hereafter referred to as "BJC 2005–2"); Retraction in: *Br J Cancer* 109(12):3132, 2013 Dec 10
- Suzuki, M., Shigematsu, H., Takahashi, T., Shivapurkar, N., Sathyanarayana, U.G., Iizasa, T., Fujisawa, T., & Gazdar, A.F. "Aberrant methylation of Reprimo in lung cancer." *Lung Cancer* 47(3):309–14; 2005 Mar (hereafter referred to as "LC 2005"); Retraction in: *Lung Cancer* 85(2):337, 2014 August
- Suzuki, M., Toyooka, S., Shivapurkar, N., Shigematsu, H., Miyajima, K., Takahashi, T., Stastny, V., Zern, A.L., Fujisawa, T., Pass, H.I., Carbone, M., & Gazdar, A.F. "Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection." *Oncogene* 24(7):1302–8, 2005 Feb 10 (hereafter referred to as "ONC 2005"); Retraction in: *Oncogene* 33(21):2814, 2014 May 22
- Suzuki, M., Shigematsu, H., Shivapurkar, N., Reddy, J., Miyajima, K., Takahashi, T., Gazdar, A.F., & Frenkel, E.P. "Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer." *Cancer Lett.* 242(2):222–30, 2006 Oct 28 (hereafter referred to as "CL 2006")
- Suzuki, M., Shigematsu, H., Shames, D.S., Sunaga, N., Takahashi, T., Shivapurkar, N., Iizasa, T., Minna, J.D., Fujisawa, T., & Gazdar, A.F. "Methylation and gene silencing of